Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells
暂无分享,去创建一个
T. Barbui | M. D’Incalci | G. Masera | C. Catapano | A. Biondi | G. Specchia | G. Giudici | M. Limonta
[1] M. Zucchetti,et al. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients , 2004, Cancer Chemotherapy and Pharmacology.
[2] M. D’Incalci,et al. Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). , 1989, Biochemical pharmacology.
[3] R. Herrmann,et al. Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. , 1987, Cancer treatment reports.
[4] J. Reiffers,et al. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. , 1987, Cancer treatment reports.
[5] M. Carli,et al. Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia. , 1987, Cancer treatment reports.
[6] C. Haanen,et al. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4‐demethoxydaunomycin , 1986, Clinical pharmacology and therapeutics.
[7] J. Griffin,et al. Clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.
[8] F. Zunino,et al. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. , 1986, Cancer research.
[9] F. Arcamone,et al. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers. , 1976, Cancer treatment reports.
[10] B. Pike,et al. Human bone marrow colony growth in agar‐gel , 1970, Journal of cellular physiology.